FIGURE 7 from Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden

JH295 treatment sensitizes viral and non-viral lymphomas to chemotherapy and has a synergistic effect on lymphoma cell death. A–C, Viability of PEL cells over time treated with vehicle control (DMSO, black bars), 2.2 µmol/L vinblastine (red bars), or ≤ 1.0 µmol/L JH295 (navy bars). Data are plotted as individual values of three independent biological replicates performed in triplicate and normalized to the 0-hour luminescence values for each treatment group. Data represent mean ± SEM and were analyzed using two-way ANOVA with Tukey multiple comparisons. ns, not significant; ****, P < 0.0001; ***, P < 0.0006; **, P = 0.0092; *, P < 0.04. D–I, Viability of lymphoma cells following 72 hours of treatment with DMSO (black boxes), rapamycin (salmon boxes), JH295 (aquamarine boxes), or rapamycin + JH295 (gray boxes). Data are plotted as individual values of three independent biological replicates performed in triplicate and normalized to the corresponding 0-hour luminescence values. Data were analyzed using one-way ANOVA with Sidak multiple comparisons. ****, P < 0.0001; ***, P = 0.0002; **, P < 0.007. D–F, virus-associated PEL cell lines. G, Nonviral DLBCL cell line. H–I, Nonviral mantle cell lymphoma cell lines.